Sandbox g55

• Enterobacter Return to Top

• Enterobacter species including E. aerogenes and E. cloacae

• 1. Empiric antimicrobial therapy pending in vitro susceptibility

• 1.1 Non–life-threatening infections or MDR-GNB prevalence < 20%

• Preferred regimen: Piperacillin-Tazobactam 3.375 g IV q6h ± Aminoglycosides
• Alternative regimen: Ciprofloxacin 400 mg IV q8–12h

• 1.2 Life-threatening infections or MDR-GNB prevalence > 20%

• Preferred regimen: Meropenem 0.5–1 g IV q8h
• Alternative regimen (1): Colistin AND Meropenem 0.5–1 g IV q8h
• Alternative regimen (2): Colistin AND Imipenem 500 mg IV q6h
• Alternative regimen (3): Colistin AND Doripenem 500 mg IV q8h
• Alternative regimen (4): Colistin AND Ertapenem 1 g IV q24h
• Alternative regimen (5): Colistin AND Fosfomycin 6 g IV q6h

• 2. In vitro susceptibility available

• 2.1 Susceptible to all tested agents

• Preferred regimen: Piperacillin-Tazobactam 3.375 g IV q6h
• Alternative regimen (1): Ciprofloxacin 400 mg IV q8–12h
• Alternative regimen (2): Cefepime 2 g IV q8h (if MIC ≤ 1 μg/mL)

• 2.2 Extended spectrum beta-lactamase (ESBL)-producing Enterobacter spp.

• Preferred regimen: Meropenem 0.5–1 g IV q8h
• Alternative regimen (1): Imipenem 500 mg IV q6h
• Alternative regimen (2): Doripenem 500 mg IV q8h
• Alternative regimen (3): Ertapenem 1 g IV q24h
• Alternative regimen (4): Cefepime 2 g IV q8h (if MIC ≤ 1 μg/mL)

• 2.3 Resistant to all tested agents

• Preferred regimen: Colistin AND Meropenem 0.5–1 g IV q8h
• Alternative regimen (1): Colistin AND Imipenem 500 mg IV q6h
• Alternative regimen (2): Colistin AND Doripenem 500 mg IV q8h
• Alternative regimen (3): Colistin AND Ertapenem 1 g IV q24h
• Alternative regimen (4): Colistin AND Minocycline 100 mg IV q12h

---

• Acanthamoeba Return to Top

• Acanthamoeba species

• 1. Granulomatous amoebic encephalitis

• Preferred regimen:

Ketoconazole, pentamidine, hydroxystilbamidine, paromomycin, 5-fluorocytosine, polymyxin, sulfadiazine, trimethoprim-sulfamethoxazole, azithromycin, and extracts of medicinal plants have been indicated as being active against Acanthamoeba in vitro

• 2. Acanthamoeba keratitis

• Preferred regimen: (Polyhexamethylene biguanide 0.02% topical OR Chlorhexidine 0.02% topical) ± (Propamidine isethionate 0.1% topical OR Hexamidine 0.1% topical)
• Note (1): Azole antifungal drugs (Ketoconazole, Itraconazole, Voriconazole) may be considered as oral or topical adjuncts.
• Note (2): The duration of therapy for Acanthamoeba keratitis may last six months to a year.

---

• Balamuthia mandrillaris Return to Top

• Balamuthia mandrillaris